4.4 Article

Insulin-like growth factor-binding protein 7 and risk of congestive heart failure hospitalization in patients with atrial fibrillation

Journal

HEART RHYTHM
Volume 18, Issue 4, Pages 512-519

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.hrthm.2020.11.028

Keywords

Atrial fibrillation; Biomarkers; Epidemiology; Heart failure; Insulin-like growth factor-binding protein 7

Funding

  1. Swiss National Science Foundation [PP00P3_159322, 33CS30_1148474, 33CS30_177520]
  2. Swiss Heart Foundation
  3. University of Basel
  4. Roche Diagnostics
  5. Boehringer-Ingelheim
  6. Sanofi-Aventis
  7. Merck Sharp Dohme
  8. Bayer
  9. Daiichi-Sankyo
  10. Pfizer/Bristol Myers Squibb
  11. Foundation for Cardiovascular Research Basel
  12. McMaster University Department of Medicine Mid-Career Research Award

Ask authors/readers for more resources

In AF patients, higher levels of IGFBP-7 were strongly associated with CHF hospitalization, and the prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.
BACKGROUND The occurrence of congestive heart failure (CHF) hospitalization among patients with atrial fibrillation (AF) is a poor prognostic marker. OBJECTIVE The purpose of this study was to assess whether insulin-like growth factor-binding protein 7 (IGFBP-7), a marker of myocardial damage, identifies AF patients at high risk for this complication. METHODS We analyzed 2 prospective multicenter observational cohort studies that included 3691 AF patients. Levels of IGFBP-7 and N-terminal pro-brain natriuretic peptide (NT-proBNP) were measured from frozen plasma samples at baseline. The primary endpoint was hospitalization for CHF. Multivariable adjusted Cox regression analyses were constructed. RESULTS Mean patient age was 69 +/- 12 years, 1028 (28%) were female, and 879 (24%) had a history of CHF. The incidence per 1000 patient-years across increasing IGFBP-7 quartiles was 7, 10, 32, and 85. The corresponding multivariable adjusted hazard ratios (aHRs) (95% confidence interval [CI]) were 1.0, 1.05 (0.63-1.77), 2.38 (1.50-3.79), and 4.37 (2.72-7.04) (P for trend <.001). In a subgroup of 2812 patients without pre-existing CHF at baseline, the corresponding aHRs were 1.0, 0.90 (0.47-1.72), 1.69 (0.94-3.04), and 3.48 (1.94-6.24) (P for trend < .001). Patients with IGFBP-7 and NT-proBNP levels above the biomarker-specific median had a higher risk of incident CHF hospitalization (aHR 5.20; 3.35-8.09) compared to those with only 1 elevated marker (elevated IGFBP-7 aHR 2.17; 1.30-3.60); elevated NT-proBNP aHR 1.97; 1.17-3.33); or no elevated marker (reference). CONCLUSION Higher plasma levels of IGFBP-7 were strongly and independently associated with CHF hospitalization in AF patients. The prognostic information provided by IGFBP-7 was additive to that of NT-proBNP.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available